HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Show Me The Money: Salaries, Red Tape Challenge FDA Recruiting

This article was originally published in The Tan Sheet

Executive Summary

FDA’s drug center continues to operate with a staffing shortage at a time of tremendous pressure to implement new authorities. Janet Woodcock is left scrambling to find senior managers to lead top initiatives. Direct hiring authority has helped but doesn’t fully address FDA’s recruiting challenges: too much red tape and too little money.

You may also be interested in...

CDER Taps Genzyme Exec As Deputy Director For Science Operations

Richard Moscicki will fill new position that will help oversee center operations and provide “executive direction,” joining fellow deputy directors Robert Temple and Douglas Throckmorton.

CDER's Generational Shift: Many New Reviewers With Little Experience

While the center for drugs has enjoyed an influx of new reviewers in the last few years, the hiring frenzy has resulted in a significant shift in CDER's makeup: 38% of reviewers in the Office of New Drugs have less than two years of on-the-job experience. Office of New Drugs director John Jenkins discusses the challenges with training the new recruits, and how industry should adapt

Reinforcements At Last: CDER Hiring Process Well Underway

FDA is in the midst of a hiring frenzy to rebuild a severely understaffed agency. The good news is that the center for drugs is about halfway through the process, with the Office of New Drugs receiving the bulk of new hires. It's not equal across review divisions-some are receiving more new people than others.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts